Citigroup
SPRY icon

Citigroup’s ARS Pharmaceuticals SPRY Stock Holding History

Citigroup’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150K Buy
18,625
+61
+0.3% +$585 ﹤0.01% 4125
2025
Q4 		$216K Buy
18,564
+9,945
+115% +$96.7K ﹤0.01% 3972
2025
Q3 		$86.6K Sell
8,619
-28,964
-77% -$416K ﹤0.01% 4317
2025
Q2 		$656K Sell
37,583
-57,627
-61% -$832K ﹤0.01% 3455
2025
Q1 		$1.2M Sell
95,210
-5,473
-5% -$65.8K ﹤0.01% 3122
2024
Q4 		$1.06M Buy
100,683
+63,461
+170% +$889K ﹤0.01% 3318
2024
Q3 		$540K Buy
37,222
+10,803
+41% +$128K ﹤0.01% 3681
2024
Q2 		$225K Sell
26,419
-71,043
-73% -$630K ﹤0.01% 3824
2024
Q1 		$996K Buy
97,462
+92,223
+1,760% +$688K ﹤0.01% 3030
2023
Q4 		$28.7K Buy
5,239
+3,472
+196% +$15.2K ﹤0.01% 4831
2023
Q3 		$6.68K Sell
1,767
-18,205
-91% -$119K ﹤0.01% 4655
2023
Q2 		$134K Sell
19,972
-33,409
-63% -$223K ﹤0.01% 4098
2023
Q1 		$348K Sell
53,381
-41,633
-44% -$320K ﹤0.01% 3383
2022
Q4 		$810K Buy
95,014
+94,596
+22,631% +$614K ﹤0.01% 2811
2022
Q3 		$2K Sell
418
-322
-44% -$1.59K ﹤0.01% 5531
2022
Q2 		$3K Sell
740
-4,944
-87% -$17.2K ﹤0.01% 5799
2022
Q1 		$20K Sell
5,684
-1,571
-22% -$6.84K ﹤0.01% 5149
2021
Q4 		$48K Buy
7,255
+4,724
+187% +$38.4K ﹤0.01% 5086
2021
Q3 		$25K Buy
2,531
+1,542
+156% +$38K ﹤0.01% 5139
2021
Q2 		$31K Buy
989
+148
+18% +$4.75K ﹤0.01% 5067
2021
Q1 		$37K Sell
841
-14,243
-94% -$674K ﹤0.01% 4878
2020
Q4 		$699K Buy
+15,084
New +$504K ﹤0.01% 3908

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citigroup's SPRY Position: Q1 2026 in Review

Citigroup increased its ARS Pharmaceuticals (SPRY) stake by 0.33% in Q1 2026, buying an estimated $585 and bringing the position to 18,625 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #4125.

Citigroup first reported a position in SPRY in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.2M in Q1 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Citigroup held 18,625 shares of ARS Pharmaceuticals worth $150K as of Q1 2026.
  • Citigroup bought 61 ARS Pharmaceuticals shares in Q1 2026, an estimated $585.
  • ARS Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4125 holding.
  • Citigroup first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's ARS Pharmaceuticals position peaked at $1.2M in Q1 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.